AXSM - Axsome Therapeutics to Present at Upcoming Investor Conferences | Benzinga
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in two upcoming investor conferences in early November. The presentation details are as follows:
- Guggenheim Healthcare Talks | 5th Annual Inflammation & Immunology Conference, on Nov. 7, 2023, at 11:10 a.m. Eastern Time. Dr. Tabuteau will participate in a fireside chat at the JW Marriot Essex House, New York City.
- 2023 Truist Securities BioPharma Symposium, on Nov. 8, 2023, at 2:25 p.m. Eastern Time. Dr. Tabuteau will participate in a panel discussion titled, "Alzheimer's Disease - Palliative Treatments," at the Lotte New York Palace Hotel, New York City.
A live webcast and archive of the Guggenheim event can be viewed on the "Webcasts & Presentations" page of the "Investors" section of the Company's website at www.axsome.com.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company's website at axsome.com. The Company may ...